Protective effect of Astragaloside IV against sepsis-induced acute lung injury in rats
Authors:
Open Access
- 4 May 2016
- journal article
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 24 (3) , 341-347
Abstract
The study aimed to explore the protective effects of AS-IV against sepsis-induced ALI. Sepsis was induced by cecal ligation and puncture (CLP) method in Sprague Dawley rats. Rats were randomly assigned into five groups: animals undergoing a sham CLP (sham group); animals undergoing CLP (CLP group); animals undergoing CLP and treated with AS-IV at 2.5 mg/kg bw (low-dose AS-IV [L-AS] group), at 5 mg/kg bw (mid-dose AS-IV [M-AS] group), and at 10 mg/kg bw (high-dose AS-IV [H-AS] group). At 6 h, 12 h and 24 h post-CLP surgery, six rats were respectively sacrificed to collect blood and lung tissue samples. The levels of arterial blood gas index, lung water content, protein level and leukocyte counts (total amount, neutrophils and lymphocytes) in bronchoalveolar lavage fluid (BALF) and cytokines such as TNF-α and IL-6 in BALF were measured at each time point in different groups. HE-staining and optical microscopy were performed to examine the pathological changes in lungs. The 72 h-survival rate of each group was also recorded. PaO2 was decreased significantly, while the lung water content, BALF protein level, cell numbers, BALF cytokine TNF-α and IL-6 levels were increased significantly for CLP group as compared with sham group. Moreover, pathological injury was observed in lung tissue indicating the successful sepsis-induced ALI model. Speaking of the effect of AS-IV, we founded that, compared with the CLP group, the AS-IV treatment groups could significantly alleviate all the above negative changes exited in the CLP group in a dose-dependent manner. What’s more, the pathological injury was also gradually improved by AS-IV treatment compared with the CLP rats. AS-IV exerts its protective effect against sepsis-induced ALI in rats via improving pulmonary ventilation function, decreasing the permeability of alveolar epithelium and capillary as well as repressing lung inflammation.Keywords
This publication has 32 references indexed in Scilit:
- Astragaloside IV, a Novel Antioxidant, Prevents Glucose-Induced Podocyte Apoptosis In Vitro and In VivoPLOS ONE, 2012
- Pathogenesis of indirect (secondary) acute lung injuryExpert Review of Respiratory Medicine, 2011
- Sepsis: definition, epidemiology, and diagnosisBMJ, 2007
- Astragaloside IV Dilates Aortic Vessels from Normal and Spontaneously Hypertensive Rats through Endothelium-Dependent and Endothelium-Independent WaysPlanta Medica, 2006
- The role of astragaloside in regeneration of the peripheral nerve systemJournal of Biomedical Materials Research Part A, 2005
- Pulmonary and extrapulmonary acute respiratory distress syndrome: are they different?Current Opinion in Critical Care, 2005
- Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemiaNeuroscience Letters, 2004
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-κB activation and adhesion molecule expressionThrombosis and Haemostasis, 2003
- Influence of direct and indirect etiology on acute outcome and 6-month functional recovery in acute respiratory distress syndromeCritical Care Medicine, 2001